Company

We improve the health and well-being of patients around the world.

Four business divisions united by a shared commitment to quality, safety and on-going innovation.

Commitment

Patients inspire the work we do every day.

We support the development of the scientific community and its research efforts.

Innovation

Take a look at the portfolio of products and therapies currently in development.

AMBAR, an ambitious research project on Alzheimer's.

Team

We strive to cultivate a friendly, diverse and inclusive work environment.

Grifols is becoming increasingly global. A diverse team will remain a key component to our future success.

Products and services

INVESTORS

Latest news

07 sep, 2018 Read more

01 aug, 2018 Grifols expands its plasma collection network by acquiring 24 Biotest centers in the United States
Read more

27 jul, 2018 Grifols increases net profits by 15% to EUR 319 million, with sustained operational revenue growth of 7%
Read more

€4.3 billion

revenue

in 2017

20,000

employees

€311 million

in R+D+i investments

in 2017

Executive report

Corporate responsibility report

Contact

Av. de la Generalitat 152-158
Parc empresarial Can Sant Joan
08174 Sant Cugat del Vallès,
Barcelona – España

Investor Relations

+34 93 571 02 21

investors@grifols.com

Subscribe to investors alerts

Subscribe to this service if you would like to receive by email the latest news for investors.

SUBSCRIBE UNSUBSCRIBE

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.